Document Detail

Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates.
MedLine Citation:
PMID:  24563374     Owner:  NLM     Status:  MEDLINE    
Resveratrol has been proposed as a potential therapeutic to improve metabolic health during pregnancy, yet little is known about the fetal effects of this maternal dietary supplement. We hypothesized that when administered to pregnant nonhuman primates (NHPs), resveratrol would increase uterine blood flow and mitigate the harmful consequences of maternal Western-style diet (WSD) consumption. NHPs were fed a WSD (36% fat) supplemented with 0.37% resveratrol throughout pregnancy. Outcomes were compared with cohorts fed WSD alone and control chow (14% fat) to distinguish between WSD and resveratrol-specific effects in these animals. In the early third trimester, uterine blood flow was measured by Doppler ultrasound before fetal delivery and tissue collection. Resveratrol resulted in 30% maternal weight loss and improved glucose tolerance, increased uterine artery volume blood flow, and decreased placental inflammation and liver triglyceride deposition. In addition, fetal pancreatic mass was enlarged by 42%, with a 12-fold increase in proliferation by Ki67 immunohistochemistry. These results demonstrate that resveratrol use during pregnancy yields improvements in maternal and placental phenotype with beneficial effects in the fetal liver but an unexplained and concerning alteration in fetal pancreatic development, which strongly cautions against the use of resveratrol by pregnant women.
Victoria H J Roberts; Lynley D Pound; Stephanie R Thorn; Melanie B Gillingham; Kent L Thornburg; Jacob E Friedman; Antonio E Frias; Kevin L Grove
Related Documents :
2724234 - Prenatal diagnosis and management of congenital heart disease.
22413724 - Pregnancy: another opportunity to raise the issue of alcohol.
15629664 - Prenatal hypoxia and cardiac programming.
20524814 - Iron overload, cardiac and other factors affecting pregnancy in thalassemia major.
10377014 - Investigation of maternal blood enriched for fetal cells: role in screening and diagnos...
9392914 - A study of gamma-aminobutyric acid (gaba) in amniotic fluid.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2014-02-21
Journal Detail:
Title:  FASEB journal : official publication of the Federation of American Societies for Experimental Biology     Volume:  28     ISSN:  1530-6860     ISO Abbreviation:  FASEB J.     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-07-29     Completed Date:  2014-10-06     Revised Date:  2014-11-14    
Medline Journal Info:
Nlm Unique ID:  8804484     Medline TA:  FASEB J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2466-77     Citation Subset:  IM    
Copyright Information:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diet / adverse effects
Dietary Supplements / adverse effects
Fetal Development / drug effects*
Liver / drug effects,  embryology
Pancreas / drug effects,  embryology
Placental Circulation / drug effects
Regional Blood Flow / drug effects
Stilbenes / adverse effects*,  blood,  contraindications,  pharmacology*
Triglycerides / blood
Uterus / blood supply
Grant Support
K01 DK090199/DK/NIDDK NIH HHS; K01-DK-090199/DK/NIDDK NIH HHS; P30 DK048520/DK/NIDDK NIH HHS; P51 OD011092/OD/NIH HHS; P51-OD-011092/OD/NIH HHS; R01 DK079194/DK/NIDDK NIH HHS; R24 DK090964/DK/NIDDK NIH HHS; R24-DK-090964/DK/NIDDK NIH HHS; S10 RR024585/RR/NCRR NIH HHS; S10-RR-024585/RR/NCRR NIH HHS
Reg. No./Substance:
0/Stilbenes; 0/Triglycerides; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients...
Next Document:  Systematic reviews to ascertain the safety of diabetes medications.